Igor Landau - Sanofi Director

SNYNF
 Stock
  

USD 88.85  6.45  6.77%   

  Director
Mr. Igor Landau was Director of Sanofi SA as of August 2004. He is also Director of INSEAD Member of the Supervisory Boards of Allianz AG and Chairman of the Supervisory Board of AdidasSalomon. Until 2012 he was Director of HSBC France among others
Age: 70  Director Since 2004      
33 1 53 77 40 00  https://www.sanofi.com
Landau previously served as Chief Executive Officer of the German subsidiary of La Compagnie du Roneo from 1968 to 1970, Management consultant at McKinsey in France from 1971 to 1975, and then held until 2004 various positions at the RhonePoulenc group, including member of the Management Board of Aventis and Chairman of the Management Board of Aventis . Between 2001 and 2005, he was a Director of Essilor, and he also served as Director of Thomson from 2002 to 2005 and as Member of the Supervisory Board of Dresdner Bank from 2003 to 2006.

Sanofi Management Efficiency

Sanofi has return on total asset (ROA) of 0.0491 % which means that it generated profit of $0.0491 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of 0.1 %, meaning that it generated $0.1 on every $100 dollars invested by stockholders. Sanofi management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 17.12 B in total debt with debt to equity ratio (D/E) of 0.3, which may suggest the company is not taking enough advantage from borrowing. Sanofi has a current ratio of 1.27, suggesting that it may have difficulties to pay its financial obligations in time and when they become due. Debt can assist Sanofi until it has trouble settling it off, either with new capital or with free cash flow. So, Sanofi's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sanofi sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sanofi to invest in growth at high rates of return. When we think about Sanofi's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing few of many executives

DIRECTOR Since

Thomas BahenAlcon AG
2015
Malcolm PradhanAlcon AG
2016
Luis HueteAlcon AG
2015
Nicholas DignamAlcon AG
2016
Carlos ToledoAlcon AG
N/A
Teresa GarridoAlcon AG
N/A
Fidel HidalgoAlcon AG
N/A
Nathan BuzzaAlcon AG
2016
Raymond BlightAlcon AG
2016
Ramon PineiroAlcon AG
N/A
Gavin WatesAlcon AG
2012
Brian LeedmanAlcon AG
2016
Josh PuckridgeAlcon AG
2015
Manuel CachafeiroAlcon AG
N/A
Josefina AlvarezAlcon AG
N/A
Ignacio LopezAlcon AG
2015
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. Sanofi was founded in 1973 and is headquartered in Paris, France. Sanofi-Aventis operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 95442 people. Sanofi [SNYNF] is a Pink Sheet which is traded between brokers as part of OTC trading.

Sanofi Leadership Team

Elected by the shareholders, the Sanofi's board of directors comprises two types of representatives: Sanofi inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sanofi. The board's role is to monitor Sanofi's management team and ensure that shareholders' interests are well served. Sanofi's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sanofi's outside directors are responsible for providing unbiased perspectives on the board's policies.
Dominique Carouge, Executive Vice President - Head of Business Transformation Member of the Executive Committee
Emmanuel Babeau, Independent Director
Roy Papatheodorou, Gen VP
Pascale Witz, Executive Vice President - Global Divisions & Strategic Commercial Development, Member of the Executive Committee and the Global Leadership Team
Serge Weinberg, Chairman, Interim CEO, Chairman of Appointments and Governance Committee and Chairman of Strategy Committee
Dieter Weinand, Executive Vice President Member of the Executive Board
Sebastien Martel, Vice President - Investor Relations and Member of the Global Leadership Team
Eva SchaeferJansen, Head Relations
Fabienne Lecorvaisier, Director
George Grofik, Vice President of Investor Relations
Karen Linehan, Member of the Executive Board, Member of the Management Board, Senior Vice President General Counsel
Klaus Pohle, Independent Director
John Reed, President - Global Research & Development, Member of the Executive Committee
Bernard Charles, Independent Director
Melanie Lee, Independent Director
Pierre Chancel, Sr Marketing
Christophe Babule, Director
Bonnie Bassler, Director
Thomas Suedhof, Independent Director
Caroline Luscombe, Executive Vice President of Human Resources, Member of the Executive Committee
Laurent Attal, Director
JeanRene Fourtou, Independent Director
JeanBaptiste Chatillon, CFO, Executive Vice President Member of the Executive Committee
Josephine Fubara, Chief Care
Christian Mulliez, Director
Robert Castaigne, Independent Director
Laurent Gilhodes, Principal Accounting
Jerome Contamine, Executive Vice President - CFO, Member of the Executive Committee and Global Leadership Team
Uwe Bicker, Independent Director
Josep Catlla, Head Communications
Claudie Haignere, Independent Director
Olivier Brandicourt, CEO, Director and Member of Strategy Committee
Paul Hudson, CEO Director
Bruno Mnard, Chief officer
Suresh Kumar, Executive Vice President - External Affairs, Member of the Executive Committee and Global Leadership Team
Dante Beccaria, Global VP
Kathleen Tregoning, Executive Vice President External Affairs; Member of the Executive Committee
William Sibold, Executive Vice President Sanofi Genzyme; Member of the Executive Committee
Peter Guenter, Executive Vice President - Global Commercial Operations, Member of the Executive Committee and the Global Leadership Team
David Loew, Member of the Global LeaderShip Team, Senior Vice President - Commercial Operations Europe
Muzammil Mansuri, Executive Vice President Strategy & Business Development, Member of the Executive Committee and the Senior Leadership Team
Diane Souza, Independent Director
Carole Piwnica, Independent Director
Elias Zerhouni, President - Global Research & Development, Member of the Executive Committee and the Global Leadership Team
Ameet Nathwani, Executive Vice President Group Chief Medical Officer, Member of the Executive Committee
Philippe Luscan, Senior Vice President - Industrial Affairs, Member of the Executive Committee and the Global Leadership Team
Roberto Pucci, Senior Vice President - Human Resources, Member of the Executive Committee and the Global Leadership Team
DavidAlexandre Gros, Executive Vice President Chief Strategy Officer and Member of the Executive Committee
Olivier Charmeil, Senior Vice President - Vaccines, Member of the Executive Committee and Global Leadership Team
Igor Landau, Director
Patrick Kron, Independent Director
Stefan Oelrich, Executive Vice President - Diabetes & Cardiovascular, Member of the Executive Committee
Gerard Kemmel, Independent Director
SuetFern Lee, Independent Director
Carsten Hellmann, Executive Vice President - Animal Health and Member of the Global Leadership Team
David Meeker, Member of the Executive Board and Executive Vice President - Genzyme and Member of the Global Leadership Team
Alan Main, Executive Vice President Consumer Healthcare; Member of the Executive Committee
Suet Lee, Independent Director

Sanofi Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right otc pink sheet is not an easy task. Is Sanofi a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Sanofi in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Sanofi's short interest history, or implied volatility extrapolated from Sanofi options trading.

Currently Active Assets on Macroaxis

Additionally, take a look at World Market Map. You can also try Transaction History module to view history of all your transactions and understand their impact on performance.

Complementary Tools for analysis

When running Sanofi price analysis, check to measure Sanofi's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sanofi is operating at the current time. Most of Sanofi's value examination focuses on studying past and present price action to predict the probability of Sanofi's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Sanofi's price. Additionally, you may evaluate how the addition of Sanofi to your portfolios can decrease your overall portfolio volatility.
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Please note, there is a significant difference between Sanofi's value and its price as these two are different measures arrived at by different means. Investors typically determine Sanofi value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sanofi's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.